Dyne Medical Group, Secures a Foothold for Global Expansion at WCET 2025
SNS 기사보내기
페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사스크랩하기Simultaneous progress in U.S. clinical-based academic validation and cooperation discussions with major corporations and medical institutions
Dyne Medical Group announced on the 29th that following its participation last year in the WCET Congress—one of the most prestigious academic conferences in the field of endourology and uro-technology, held in Seoul—it also took part this year in the event held in Phoenix, Arizona, U.S. The company emphasized that it advanced both U.S. clinical-based academic validation of its products and discussions on cooperation with global corporations and medical institutions, thereby strengthening its presence.
Roger Sur, Professor at UC San Diego and an authority in the field of kidney stones, delivers a lecture on the clinical differentiation of URUS.
One of the most notable products at this year’s congress was Dyne Medical Group’s URUS (single-use flexible ureteroscope).
In his lecture, Professor Roger Sur of UC San Diego School of Medicine introduced URUS’s “6 o’clock working channel” design together with U.S. clinical results, stating, “For the first time in 30 years since the introduction of the flexible ureteroscope, the position of the working channel has changed. This is of great significance. Dyne Medical Group’s technology can truly be described as ‘moving the needle.’”
Following this, Professor Hyung-Joon Kim of Seoul National University Bundang Hospital and Professor Bum-Soo Kim of Kyungpook National University Hospital presented clinical findings based on their own use of URUS in kidney stone patients in Korea. They highlighted URUS’s clinical effectiveness in terms of field of vision, maneuverability, and accessibility to renal stones enabled by the 6 o’clock working channel. The lecture was attended by more than 150 participants, exceeding the limited seating capacity, and was held with great success.
The U.S.-based congress lecture attracted a large number of local urologists. The fact that a Korean medical device manufacturer and Korean scholars presented together in such a setting was a meaningful achievement, further elevating the status of K-Medical.
During the WCET 2025 congress, Dyne Medical Group’s exhibition booth was visited by representatives from major university hospitals and leading medical institutions in the U.S. They sought to understand the clinical significance of URUS, experienced product demonstrations, and even requested clinical trials at their hospitals, leading to active discussions from a practical usage perspective.
Dyne Medical Group explained that in order to translate these on-site responses into actual usage and sales, it will carry out follow-up measures together with its U.S. regional distributors, who are under contract, so that hospital demonstrations can lead to product adoption and revenue generation.
Local healthcare professionals listening to explanations at Dyne Medical Group’s booth during WCET 2025.
The company further announced that it will continue its clinical research collaborations with influential U.S. medical institutions on Dyne Medical Group products, building long-term developmental relationships and solidifying the foundation for an expanded global clinical network.
Another product from Dyne Medical Group that drew attention at this year’s congress was Port-C. Port-C, with its lever-based fine control mechanism, enables precise one-handed micro-movement (approximately 0–6 mm) of treatment tools such as laser fibers and baskets, thereby improving both procedural efficiency and safety.
A notable feature is that Port-C is compatible not only with Dyne Medical Group’s devices but also with other companies’ endoscopes and accessories, opening the door to broader collaborative opportunities.
According to the company, Port-C is preparing for U.S. FDA clearance early next year. Based on the global patented technology applied to Port-C, its potential has been recognized not only within the subspecialty of urology beyond kidney stone treatment, but also in other surgical fields outside urology. Related to this, it has been reported that numerous specific discussions with global corporations took place on-site at WCET.
Meanwhile, Dyne Medical Group recently entered into a strategic product development collaboration and global supply agreement with Swiss company EMS for the next-generation renal endoscopy system. As a result, there are growing expectations that the conversations at this congress could move beyond mere possibilities and develop into actual collaborations.
Sunghoon Lee, CEO of Dyne Medical Group, stated, “It is highly meaningful that both academic validation based on U.S. clinical data and collaboration discussions with medical institutions and global corporations advanced simultaneously. We will create a virtuous cycle of expanding clinical evidence → enhancing partnerships → accelerating market entry, centered on URUS and Port-C.”
SNS 기사보내기
페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사스크랩하기
Dyne Medical Group, Secures a Foothold for Global Expansion at WCET 2025
SNS 기사보내기
페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사스크랩하기Simultaneous progress in U.S. clinical-based academic validation and cooperation discussions with major corporations and medical institutions
Dyne Medical Group announced on the 29th that following its participation last year in the WCET Congress—one of the most prestigious academic conferences in the field of endourology and uro-technology, held in Seoul—it also took part this year in the event held in Phoenix, Arizona, U.S. The company emphasized that it advanced both U.S. clinical-based academic validation of its products and discussions on cooperation with global corporations and medical institutions, thereby strengthening its presence.
One of the most notable products at this year’s congress was Dyne Medical Group’s URUS (single-use flexible ureteroscope).
In his lecture, Professor Roger Sur of UC San Diego School of Medicine introduced URUS’s “6 o’clock working channel” design together with U.S. clinical results, stating, “For the first time in 30 years since the introduction of the flexible ureteroscope, the position of the working channel has changed. This is of great significance. Dyne Medical Group’s technology can truly be described as ‘moving the needle.’”
Following this, Professor Hyung-Joon Kim of Seoul National University Bundang Hospital and Professor Bum-Soo Kim of Kyungpook National University Hospital presented clinical findings based on their own use of URUS in kidney stone patients in Korea. They highlighted URUS’s clinical effectiveness in terms of field of vision, maneuverability, and accessibility to renal stones enabled by the 6 o’clock working channel. The lecture was attended by more than 150 participants, exceeding the limited seating capacity, and was held with great success.
The U.S.-based congress lecture attracted a large number of local urologists. The fact that a Korean medical device manufacturer and Korean scholars presented together in such a setting was a meaningful achievement, further elevating the status of K-Medical.
During the WCET 2025 congress, Dyne Medical Group’s exhibition booth was visited by representatives from major university hospitals and leading medical institutions in the U.S. They sought to understand the clinical significance of URUS, experienced product demonstrations, and even requested clinical trials at their hospitals, leading to active discussions from a practical usage perspective.
Dyne Medical Group explained that in order to translate these on-site responses into actual usage and sales, it will carry out follow-up measures together with its U.S. regional distributors, who are under contract, so that hospital demonstrations can lead to product adoption and revenue generation.
The company further announced that it will continue its clinical research collaborations with influential U.S. medical institutions on Dyne Medical Group products, building long-term developmental relationships and solidifying the foundation for an expanded global clinical network.
Another product from Dyne Medical Group that drew attention at this year’s congress was Port-C. Port-C, with its lever-based fine control mechanism, enables precise one-handed micro-movement (approximately 0–6 mm) of treatment tools such as laser fibers and baskets, thereby improving both procedural efficiency and safety.
A notable feature is that Port-C is compatible not only with Dyne Medical Group’s devices but also with other companies’ endoscopes and accessories, opening the door to broader collaborative opportunities.
According to the company, Port-C is preparing for U.S. FDA clearance early next year. Based on the global patented technology applied to Port-C, its potential has been recognized not only within the subspecialty of urology beyond kidney stone treatment, but also in other surgical fields outside urology. Related to this, it has been reported that numerous specific discussions with global corporations took place on-site at WCET.
Meanwhile, Dyne Medical Group recently entered into a strategic product development collaboration and global supply agreement with Swiss company EMS for the next-generation renal endoscopy system. As a result, there are growing expectations that the conversations at this congress could move beyond mere possibilities and develop into actual collaborations.
Sunghoon Lee, CEO of Dyne Medical Group, stated, “It is highly meaningful that both academic validation based on U.S. clinical data and collaboration discussions with medical institutions and global corporations advanced simultaneously. We will create a virtuous cycle of expanding clinical evidence → enhancing partnerships → accelerating market entry, centered on URUS and Port-C.”
SNS 기사보내기
페이스북(으)로 기사보내기 트위터(으)로 기사보내기 카카오스토리(으)로 기사보내기 URL복사(으)로 기사보내기 이메일(으)로 기사보내기 다른 공유 찾기 기사스크랩하기